FlowBeams, a MedTech spin-off from the University of Twente, proudly announces receiving the highly competitive the European Innovation Council (EIC) Transition grant, €2.5 million. This exceptional accomplishment underscores the remarkable potential of FlowBeams to continue advancing the field of needle-free injection technology.
The EIC Transition grant awarded to FlowBeams as only beneficiary highlights the exceptional quality of the scientific foundations and groundbreaking nature of the venture. The iSENS project will benefit from almost a decade of scientific results led by Prof. David Fernandez Rivas, and previous funding from the European Research Council (ERC) and the Dutch Research Council (NWO). FlowBeams has been supported by NovelT, MESA+ and TechMed Institute from the University of Twente.
Team FlowBeams
commercialize
This financial boost will accelerate the plans of FlowBeams to innovate minimal invasive injection technology. The company wants to commercialize its novel platform technology, starting with the cosmetics market but eying the more ambitious human drug pharma. FlowBeams will expand its team, starting with Jelle Schoppink, PhD candidate in the Mesoscale Chemical Systems Group. The team’s activities will also contribute to the local and regional deep-tech innovation ecosystem.
"We are honored and grateful for the support given by the European Innovation Council and its confidence in our vision," stated Lea Milovich, CEO of FlowBeams. "This grant represents a significant milestone in our journey towards realizing the full potential of our needle-free injection technology and making a meaningful impact in the healthcare and cosmetic industries."
The time could not be more appropriate, with the recent developments in deep-tech and microchip technology in the region. FlowBeams looks forward to strengthen the ecosystem in Twente and put our region on the international map.
